Cargando…

Application of rivaroxaban in patients with non-valvular atrial fibrillation and end-stage kidney disease: A systematic review and meta-analysis

BACKGROUND: Nowadays, the number of patients with non-valvular atrial fibrillation (NVAF) complicated by end-stage renal disease (ESKD) is increasing. There are significant challenges in anticoagulation with prescription drugs because of the high risk of bleeding and embolism among these patients. H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Zhenzhen, Wang, Jieya, Yuan, Ye, Cheng, Tian, Ren, Feifei, Wang, Songsong, Zhang, Zhiqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951003/ https://www.ncbi.nlm.nih.gov/pubmed/36844734 http://dx.doi.org/10.3389/fcvm.2023.1021959

Ejemplares similares

A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk
por: Liu, Peng-Hui, et al.
Publicado: (2022)

Efficacy and safety evaluation of rivaroxaban vs. warfarin among non-valvular atrial fibrillation patients undergoing lower extremity revascularization
por: Yu, Qingyuan, et al.
Publicado: (2022)

Comparison of Inflammatory Mediators in Patients With Atrial Fibrillation Using Warfarin or Rivaroxaban
por: Martins, Gabriela Lopes, et al.
Publicado: (2020)

Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain
por: Rubio-Terrés, Carlos, et al.
Publicado: (2016)

Expression Profiles of Circular RNA in Human Atrial Fibrillation With Valvular Heart Diseases
por: Zhu, Xiyu, et al.
Publicado: (2020)

Real-World Data of Anticoagulant Treatment in Non-valvular Atrial Fibrillation
por: Calderon, Jose Miguel, et al.
Publicado: (2022)

Population pharmacokinetic analysis for dabigatran etexilate in Chinese patients with non-valvular atrial fibrillation
por: Liu, Ya-ou, et al.
Publicado: (2022)

A Study of Cardiogenic Stroke Risk in Non-valvular Atrial Fibrillation Patients
por: Song, Ziliang, et al.
Publicado: (2020)

The value of left atrial longitudinal strain in evaluating left atrial appendage spontaneous echo contrast in non-valvular atrial fibrillation
por: Ma, Chang sheng, et al.
Publicado: (2023)

Nomogram to Predict Left Atrial Thrombus or Spontaneous Echo Contrast in Patients With Non-valvular Atrial Fibrillation
por: Li, Zhitong, et al.
Publicado: (2021)

Left Atrial Thrombus in Patients With Non-valvular Atrial Fibrillation: A Cross-Sectional Study in China
por: Shi, Shaobo, et al.
Publicado: (2022)

A Review of Biomarkers for Ischemic Stroke Evaluation in Patients With Non-valvular Atrial Fibrillation
por: Shang, Luxiang, et al.
Publicado: (2021)

Platelet CD36 links overweight and a prothrombotic phenotype in patients with non-valvular atrial fibrillation
por: Wang, Hua, et al.
Publicado: (2022)

Stroke prevention with rivaroxaban in higher‐risk populations with atrial fibrillation
por: Diener, H.‐C., et al.
Publicado: (2015)

Incidence of atrial functional tricuspid regurgitation and its correlation with tricuspid valvular deformation in patients with persistent atrial fibrillation
por: Yamamoto, Yuko, et al.
Publicado: (2022)

The safety and efficacy of direct oral anticoagulants among chronic kidney disease patients on dialysis with non-valvular atrial fibrillation: a meta-analysis
por: Mapili, Jerahmeel Aleson L., et al.
Publicado: (2023)

Left atrial epicardial adipose tissue is associated with low voltage zones in the left atrium in patients with non-valvular atrial fibrillation
por: Shao, Yameng, et al.
Publicado: (2022)

Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?
por: Lin, Dong, et al.
Publicado: (2021)

Genetically Predicted Atrial Fibrillation and Valvular Heart Disease: A Two-Sample Mendelian Randomization Study
por: Gao, Jie, et al.
Publicado: (2022)

Quantitative acetylated proteomics on left atrial appendage tissues revealed atrial energy metabolism and contraction status in patients with valvular heart disease with atrial fibrillation
por: Tu, Tao, et al.
Publicado: (2022)

Direct Acting Oral Anticoagulant vs. Warfarin in the Prevention of Thromboembolism in Patients With Non-valvular Atrial Fibrillation With Valvular Heart Disease—A Systematic Review and Meta-Analysis
por: Martha, Januar Wibawa, et al.
Publicado: (2021)

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
por: Breithardt, Günter, et al.
Publicado: (2016)

Renal outcomes of rivaroxaban compared with warfarin in Asian patients with nonvalvular atrial fibrillation: A nationwide population-based cohort study
por: Lee, So-Ryoung, et al.
Publicado: (2023)

Comparative analysis of left atrial appendage closure efficacy and outcomes by CHA(2)DS(2)-VASc score group in patients with non-valvular atrial fibrillation
por: Zhao, Mingzhong, et al.
Publicado: (2022)

Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study
por: Jaksa, Ashley, et al.
Publicado: (2022)

Influence of gender on the clinical outcomes of Asian non-valvular atrial fibrillation patients: insights from the prospective multicentre COOL-AF registry
por: Krittayaphong, Rungroj, et al.
Publicado: (2021)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

Machine learning-based analysis of risk factors for atrial fibrillation recurrence after Cox-Maze IV procedure in patients with atrial fibrillation and chronic valvular disease: A retrospective cohort study with a control group
por: Jiang, Zenan, et al.
Publicado: (2023)

Does Chronic Kidney Disease Result in High Risk of Atrial Fibrillation?
por: Zhang, Dapeng, et al.
Publicado: (2019)

Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease
por: Fu, Chung-Ming, et al.
Publicado: (2021)

Effect of Preablation Glycemic Control on Outcomes of Atrial Fibrillation Patients With Diabetes Mellitus Following Valvular Surgery Combined With the Cox-Maze IV Procedure
por: Peng, Zhan, et al.
Publicado: (2022)

Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation
por: Wang, Li, et al.
Publicado: (2013)

Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care
por: Johnson, Michelle E, et al.
Publicado: (2016)

Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry
por: Camm, A John, et al.
Publicado: (2017)

Comparison of the Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Bitar, Yasmin de Souza Lima, et al.
Publicado: (2021)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non‐valvular atrial fibrillation and heart failure
por: Martinez, Brandon K., et al.
Publicado: (2018)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
por: Norby, Faye L., et al.
Publicado: (2017)

Rivaroxaban in atrial fibrillation
por: Giorgi, Mariano A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_sq6lbr8er2936p6u47dlir2b69